Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Tumor Progression02:07

Tumor Progression

7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Turmoil and breakthroughs: Highlights and growing pains in breast cancer therapy 2025<b>-</b>2026.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu·2026
Same author

Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu·2026
Same author

Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University·2026
Same author

Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort Study.

Patient preference and adherence·2026
Same author

Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy.

NPJ precision oncology·2026
Same author

Standard: human breast cancer organoids derived from diverse clinical sample sources.

Cell regeneration (London, England)·2026

Related Experiment Video

Updated: Dec 12, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.6K

Progress in systemic therapy for triple-negative breast cancer.

Hongnan Mo1, Binghe Xu2

  • 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Frontiers of Medicine
|August 14, 2020
PubMed
Summary

Triple-negative breast cancer (TNBC) is aggressive and genetically diverse. Advances in genetic analysis offer new therapeutic targets, but selecting the right patients for treatment remains challenging.

Keywords:
immunotherapytargeted therapytriple-negative breast cancer

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Experiment Videos

Last Updated: Dec 12, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.6K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Area of Science:

  • Oncology
  • Genetics
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype.
  • TNBC is characterized by a heterogeneous genetic profile.
  • Chemotherapy is effective in only a subset of TNBC patients, with drug resistance being a significant issue.

Purpose of the Study:

  • To review recent advances in the genetic analysis of TNBC.
  • To highlight novel therapeutic targets and precision medicine approaches for TNBC.
  • To discuss the challenges in patient selection for TNBC treatment strategies.

Main Methods:

  • Review of genetic analyses in TNBC.
  • Evaluation of current and emerging treatment strategies.
  • Analysis of clinical trial data for TNBC therapies.

Main Results:

  • Significant progress in understanding TNBC genetics.
  • Identification of novel therapeutic targets.
  • Development of advanced treatment strategies including immunotherapy and targeted drugs.

Conclusions:

  • Genetic insights have improved TNBC treatment strategies.
  • New approaches like immune checkpoint inhibitors and targeted drugs show promise.
  • Effective patient selection remains a critical challenge in clinical practice.